StockIQpro
NYSE:CATX

Perspective Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Perspective Therapeutics, Inc. reported net income of −$103.1M in fiscal 2025. Free cash flow was −$95.2M, and the diluted share count rose 14.6%.Summary generated from Perspective Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−43.9%
Return on equity−41.4%
Debt / equity0.01
Free cash flow−$95.2M
FCF marginn/a
Share count change+14.6%

Financials

Fiscal years, $M
Item2022202320242025
Revenue01n/an/a
Operating income−9−41−91−114
Net income−11−47−79−103
Free cash flow−11−38−73−95

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations